Mondelez International, Inc. (MDLZ) Stock Forecast
Data as of Jul 31, 2026Consumer Defensive · Current price $62.44 (-1.05%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Apr 13, 2026 | Rob Dickerson | BTIG | $70.00 | +12.1% |
| Feb 4, 2026 | Brian Holland | D.A. Davidson | $62.00 | -0.7% |
| Feb 4, 2026 | Megan Alexander Clapp | Morgan Stanley | $66.00 | +5.7% |
| Feb 4, 2026 | Michael Lavery | Piper Sandler | $64.00 | +2.5% |
| Jan 21, 2026 | Thomas Palmer | Coker Palmer | $69.00 | +10.5% |
| Jan 5, 2026 | Chris Carey | Wells Fargo | $62.00 | -0.7% |
| Oct 29, 2025 | Nik Modi | RBC Capital | $67.00 | +7.3% |
| Oct 29, 2025 | Alexia Howard | Bernstein | $84.00 | +34.5% |
| Oct 29, 2025 | Megan Alexander Clapp | Morgan Stanley | $68.00 | +8.9% |
| Oct 8, 2025 | Peter Grom | UBS | $65.00 | +4.1% |
| Jan 8, 2025 | Chris Carey | Wells Fargo | $61.00 | -2.3% |
| Oct 30, 2024 | Michael Lavery | Piper Sandler | $84.00 | +34.5% |
| Oct 30, 2024 | Chris Carey | Wells Fargo | $78.00 | +24.9% |
| Oct 23, 2024 | Michael Lavery | Piper Sandler | $74.00 | +18.5% |
| Oct 15, 2024 | Peter Galbo | Bank of America Securities | $84.00 | +34.5% |
| Aug 9, 2024 | Michael Lavery | Piper Sandler | $76.00 | +21.7% |
| Jul 31, 2024 | Brian Holland | D.A. Davidson | $75.00 | +20.1% |
| Jun 5, 2024 | Michael Lavery | Piper Sandler | $78.00 | +24.9% |
| May 31, 2024 | Rob Dickerson | Jefferies | $78.00 | +24.9% |
| Apr 9, 2024 | Michael Lavery | Piper Sandler | $81.00 | +29.7% |
Top Analysts Covering MDLZ
MDLZ vs Sector & Market
| Metric | MDLZ | Consumer Defensive Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.32 | 2.56 | 2.42 |
| Analyst Count | 22 | 10 | 19 |
| Target Upside | +10.4% | +1206.7% | +18.0% |
| P/E Ratio | 33.21 | 11.33 | 43.33 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $38.78B | $39.62B | $39.99B | 19 |
| 2027-03-31 | $9.90B | $10.05B | $10.23B | 5 |
| 2027-06-30 | $9.28B | $9.42B | $9.58B | 5 |
| 2027-09-30 | $10.08B | $10.23B | $10.41B | 5 |
| 2027-12-31 | $10.85B | $11.01B | $11.20B | 5 |
| 2028-03-31 | $10.24B | $10.39B | $10.57B | 4 |
| 2028-06-30 | $9.50B | $9.64B | $9.81B | 4 |
| 2028-09-30 | $10.37B | $10.53B | $10.71B | 4 |
| 2028-12-31 | $11.21B | $11.38B | $11.58B | 4 |
| 2029-12-31 | $42.32B | $43.14B | $43.84B | 9 |
| 2030-12-31 | $43.37B | $44.21B | $44.93B | 13 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $2.92 | $3.03 | $3.08 | 14 |
| 2027-03-31 | $0.74 | $0.76 | $0.77 | 5 |
| 2027-06-30 | $0.74 | $0.76 | $0.78 | 5 |
| 2027-09-30 | $0.90 | $0.92 | $0.94 | 5 |
| 2027-12-31 | $0.91 | $0.93 | $0.95 | 5 |
| 2028-03-31 | $0.79 | $0.81 | $0.82 | 7 |
| 2028-06-30 | $0.79 | $0.80 | $0.82 | 6 |
| 2028-09-30 | $0.98 | $1.00 | $1.02 | 6 |
| 2028-12-31 | $0.97 | $0.99 | $1.01 | 7 |
| 2029-12-31 | $3.71 | $3.81 | $3.89 | 4 |
| 2030-12-31 | $3.97 | $4.07 | $4.16 | 2 |
Frequently Asked Questions
What is the analyst consensus for MDLZ?
The consensus among 22 analysts covering Mondelez International, Inc. (MDLZ) is Buy with an average price target of $67.00.
What is the highest price target for MDLZ?
The highest price target for MDLZ is $84.00, set by Alexia Howard at Bernstein on 2025-10-29.
What is the lowest price target for MDLZ?
The lowest price target for MDLZ is $61.00, set by Chris Carey at Wells Fargo on 2025-01-08.
How many analysts cover MDLZ?
22 analysts have issued ratings for Mondelez International, Inc. in the past 12 months.
Is MDLZ a buy or sell right now?
Based on 22 analyst ratings, MDLZ has a consensus rating of Buy (2.32/5) with a +10.4% upside to the consensus target of $67.00.
What are the earnings estimates for MDLZ?
Analysts estimate MDLZ will report EPS of $3.03 for the period ending 2026-12-31, with revenue estimated at $39.62B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.